FDA Demands Transparency from Drug Developers, Urges Public Disclosure of Trial Results
The Food and Drug Administration (FDA) has issued a directive to over 2,200 drug developers, reminding them of their legal obligation to publicly disclose clinical trial results on the federal database, clinicaltrials.gov. This move is part of the FDA's broader initiative to enhance transparency within the pharmaceutical industry. According to the FDA, approximately 29.6% of mandated studies have not complied with this requirement, leading to significant gaps in the public record. The FDA emphasizes that the failure to report, particularly negative outcomes, skews the perception of drug development by overrepresenting successes. The agency is seeking voluntary compliance but warns that non-compliance could result in civil penalties or criminal prosecution. This transparency push aligns with the FDA's ongoing campaign to foster accountability and professionalism in the industry. 
